Antonio C. Wolff
Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline focused update
Wolff, Antonio C.; Hammond, M. Elizabeth Hale; Allison, Kimberly H.; Harvey, Brittany E.; Mangu, Pamela B.; Bartlett, John M.S.; Bilous, Michael; Ellis, Ian O.; Fitzgibbons, Patrick; Hanna, Wedad; Jenkins, Robert B.; Press, Michael F.; Spears, Patricia A.; Vance, Gail H.; Viale, Giuseppe; McShane, Lisa M.; Dowsett, Mitchell
Authors
M. Elizabeth Hale Hammond
Kimberly H. Allison
Brittany E. Harvey
Pamela B. Mangu
John M.S. Bartlett
Michael Bilous
Ian O. Ellis
Patrick Fitzgibbons
Wedad Hanna
Robert B. Jenkins
Michael F. Press
Patricia A. Spears
Gail H. Vance
Giuseppe Viale
Lisa M. McShane
Mitchell Dowsett
Abstract
© 2018 College of American Pathologists Published by the College of American Pathologists Allen Press, Inc. Purpose. - To update key recommendations of the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) human epidermal growth factor receptor 2 (HER2) testing in breast cancer guideline. Methods. - Based on the signals approach, an Expert Panel reviewed published literature and research survey results on the observed frequency of less common in situ hybridization (ISH) patterns to update the recommendations. Recommendations. - Two recommendations addressed via correspondence in 2015 are included. First, immunohistochemistry (IHC) 2+ is defined as invasive breast cancer with weak to moderate complete membrane staining observed in >10% of tumor cells. Second, if the initial HER2 test result in a core needle biopsy specimen of a primary breast cancer is negative, a new HER2 test may (not ''must'') be ordered on the excision specimen based on specific clinical criteria. The HER2 testing algorithm for breast cancer is updated to address the recommended workup for less common clinical scenarios (approximately 5% of cases) observed when using a dual-probe ISH assay. These scenarios are described as ISH group 2 (HER2/ chromosome enumeration probe 17 [CEP17] ratio ≥2.0; average HER2 copy number
Citation
Wolff, A. C., Hammond, M. E. H., Allison, K. H., Harvey, B. E., Mangu, P. B., Bartlett, J. M., Bilous, M., Ellis, I. O., Fitzgibbons, P., Hanna, W., Jenkins, R. B., Press, M. F., Spears, P. A., Vance, G. H., Viale, G., McShane, L. M., & Dowsett, M. (2018). Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline focused update. Archives of Pathology and Laboratory Medicine, 142(11), 1364-1382. https://doi.org/10.5858/arpa.2018-0902-sa
Journal Article Type | Article |
---|---|
Acceptance Date | May 30, 2018 |
Online Publication Date | Nov 1, 2018 |
Publication Date | Nov 1, 2018 |
Deposit Date | Aug 8, 2019 |
Publicly Available Date | Aug 8, 2019 |
Journal | Archives of Pathology & Laboratory Medicine |
Print ISSN | 0003-9985 |
Electronic ISSN | 1543-2165 |
Publisher | College of American Pathologists |
Peer Reviewed | Peer Reviewed |
Volume | 142 |
Issue | 11 |
Pages | 1364-1382 |
DOI | https://doi.org/10.5858/arpa.2018-0902-sa |
Public URL | https://nottingham-repository.worktribe.com/output/2406986 |
Publisher URL | https://www.archivesofpathology.org/doi/10.5858/arpa.2018-0902-SA |
Contract Date | Aug 8, 2019 |
Files
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer
(1.5 Mb)
PDF
Downloadable Citations
About Repository@Nottingham
Administrator e-mail: discovery-access-systems@nottingham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2025
Advanced Search